David Rosmarin MD

Dermatology•Indianapolis, IN

Instructor in Dermatology, Brigham and Women's Hospital

Join to View Full Profile

550 University BlvdSte 3240Indianapolis, IN 46202
Phone+1 317-948-8657
Fax+1 317-944-7051

Education & Training

Boston University Medical CenterResidency, Dermatology, 2006 - 2009
New York Presbyterian Hospital (Cornell Campus)Internship, Internal Medicine, 2005 - 2006
New York University School of MedicineClass of 2005

Certifications & Licensure

IN State Medical License 2022 - 2025
MA State Medical License 2008 - 2023
NY State Medical License 2013 - 2016
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2013

Clinical Trials

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis Start of enrollment: 2016 Apr 01
Completed
Phase 3
Topical Ruxolitinib for the Treatment of Vitiligo Start of enrollment: 2016 Jan 01
Completed
Phase 2
Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa Start of enrollment: 2016 Jul 11
Completed
Early Phase 1
Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Start of enrollment: 2017 Apr 03
Terminated
Early Phase 1
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis Start of enrollment: 2019 Aug 12
Active, not recruiting
Phase 3
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis Start of enrollment: 2019 Oct 29
Completed
Phase 3
Topical Crisaborole in Patients with Alopecia Areata Start of enrollment: 2020 Mar 06
WITHDRAWN
PHASE2
Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab Start of enrollment: 2020 Aug 01
Completed
Phase 2
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) Start of enrollment: 2020 Jun 15
ACTIVE_NOT_RECRUITING
PHASE3
A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) Start of enrollment: 2020 Nov 17
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

3 citations
A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice: First Analysis Cycle of a Sequential Moni...
Maria C Schneeweiss, Robert J Glynn, Richard Wyss, Priyanka Anand, Yinzhu Jin
The Journal of Investigative Dermatology. 2025-05-01
The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16...
Emma Guttman-Yassky, David Rosmarin, Marjolein de Bruin-Weller, Stephan Weidinger, Thomas Bieber
Journal of the American Academy of Dermatology. 2025-05-01
Measles Resurgence: What Every Dermatologist Should Know.
Esther Freeman, Christine Li, David Castillo, Sukhjeet Ahuja, Yvonne E Chiu
Journal of the American Academy of Dermatology. 2025-04-08

Press Mentions

Maintenance of Low Eczema Activity Seen After About 80 Days off TapinarofMarch 14th, 2025
Adolescents with Vitiligo Achieve Higher Repigmentation Rates with Topical Ruxolitinib Than AdultsJuly 16th, 2024
Seeing Red with DupilumabMarch 1st, 2023
Join now to see all